|Bid||10.10 x 3100|
|Ask||11.77 x 3100|
|Day's Range||11.58 - 11.97|
|52 Week Range||6.22 - 25.29|
|Beta (3Y Monthly)||4.37|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 7, 2017 - Mar 13, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||27.20|
Spectrum Pharmaceuticals (SPPI) announced today that an overview of the company's business strategy and development-stage programs will be given at the Guggenheim Healthcare Talks Idea Forum | Oncology Day being held in New York. The company presentation is on Thursday, February 14, 2019, at 9:30 AM ET. A live webcast of Spectrum's presentation will be available at http://www.sppirx.com.
popped Thursday after the company announced that it was selling its marketed portfolio of seven Food and Drug Administration-approved products to Acrotech Biopharma for $160 million up front, with a potential for another $140 million in regulatory and sales-based milestones. The company will reduce its staff size by about 40% as a result of the deal, with the impacted staff transitioning over to Acrotech. "This divestiture marks a major strategic shift for Spectrum to ensure laser-focus on novel, oncology drug development and commercialization," said Joe Turgeon, president and CEO of Spectrum Pharmaceuticals.
Spectrum Pharmaceuticals Inc. said Thursday it has reached an agreement to sell its portfolio of seven FDA-approved hematology/oncology products to Acrotech Biopharma L.L.C. Spectrum said it will receive $160 million in an upfront cash payment and be entitled to up to $140 million milestone payments on reaching certain regulatory and sales goals. The company said its staff will be reduced by about 40% with most transitioning to Acrotech. The remaining staff will focus on the launch of it two late-stage pipeline treatments, ROLONTIS and poziotinib, which are cancer drugs. Shares were halted for the news, but have fallen 46.1% in the last 12 months, while the S&P 500 has fallen 6.7%.
HENDERSON, Nev.-- -- Spectrum will receive $160 million in an upfront cash payment and up to $140 million in regulatory and sales-based milestones Staff size will be reduced by approximately 40 percent with the majority of impacted staff transitioning to Acrotech Spectrum will retain a core group of commercial talent to lead the launch of ROLONTIS ® and poziotinib Management to host a webcast on ...
Spectrum Pharma (SPPI) completes enrollment in the first cohort of a phase II study on poziotinib for previously treated NSCLC patients with EGFR exon 20 insertion mutations. Shares rise.
Spectrum Pharmaceuticals, Inc. (SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced full enrollment of cohort 1 (N=87) for previously treated Non-Small Cell Lung Cancer (NSCLC) patients with EGFR exon 20 insertion mutations with sites across the U.S., Europe, and Canada. The EGFR previously treated cohort is part of the ZENITH20 trial – an open-label, multi-center, global Phase 2 trial evaluating NSCLC patients with EGFR or HER2 exon 20 insertion mutations. “The rapid rate at which we enrolled our Phase 2 previously treated EGFR exon 20 insertion mutations cohort speaks to the critical unmet medical need and demonstrates that the poziotinib program is aggressively advancing,” said Joe Turgeon, President and Chief Executive Officer of Spectrum Pharmaceuticals.
Spectrum Pharma (SPPI) petitions for a BLA to the FDA regarding its lead pipeline candidate, Rolontis, to address chemotherapy-induced neutropenia in patients with breast cancer.
The biopharma announced that one of its drug candidates is closer to hitting the market, but investors aren't in a celebratory mood.
In the first nine months of 2018, Spectrum Pharmaceuticals (SPPI) reported a net income and diluted EPS of -$70.8 million and -$0.69, respectively—compared to -$62.7 million and -$0.78 in the same period the previous year.
In the first nine months of 2018, Spectrum Pharmaceuticals’ (SPPI) net revenues declined ~20% YoY (year-over-year) to $79.9 million from $99.8 million. During this period, the company’s net product sales were $76.4 million, which reflected an ~13% YoY decline. During the same period, the company’s revenues from license fees and services were $3.5 million, which reflected an ~70% YoY decline.
On December 21, Spectrum Pharmaceuticals’ stock price closed at $7.24, which was ~13.30% growth from the close of $6.39 on December 20. On December 20, Spectrum Pharmaceuticals’ stock price declined ~38.79% to $6.39 from the close of $10.44 on December 19. The company hit its 52-week low of $6.22 on December 20.
Spectrum Pharmaceuticals, Inc. (SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, announced today that the company submitted a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for ROLONTIS® (eflapegrastim). “ROLONTIS is an important and significant future growth driver for our company,” said Joe Turgeon, President and CEO of Spectrum Pharmaceuticals. The BLA for ROLONTIS is supported by data from two identically designed Phase 3 clinical trials, ADVANCE and RECOVER, which evaluated the safety and efficacy of ROLONTIS in 643 early-stage breast cancer patients for the treatment of neutropenia due to myelosuppressive cytoxic chemotherapy.
Spectrum Pharma announced Wednesday after the close that the FDA declined to accord Breakthrough Therapy Designation, or BTD, for poziotinib, its pipeline candidate that is being evaluated in the ZENITH20 study in patients with metastatic non-small cell lung cancer and EGFR exon 20 tumor mutations. Now that the BTD designation is being denied, the existing development plan and timeline for a NDA filing based on the first cohort of the ZENITH20 trial still holds, the company said.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Dec. 19) Endocyte, Inc. (NASDAQ: ECYT ) Down In The Dumps (Biotech ...
NEW YORK, NY / ACCESSWIRE / December 20, 2018 / U.S. equities closed down on Wednesday as the anticipated interest rate increase was confirmed by the Federal Reserve, following Chairman Jerome Powell’s ...
Tilray TLRY shares surged as much as 19 percent after hours after the company announced it entered into a $100 million joint venture with AB InBev. The beer brewer and Tilray will study non-alcoholic cannabis-based beverages in Canada. The joint venture, in which both companies will invest $50 million each, will study non-alcoholic beverages containing THC, the intoxicating chemical compound in marijuana, as well as CBD, the non-psychoactive compound.
Shares of Spectrum Pharmaceuticals Inc. fell more than 20% in the extended session Wednesday after the company said that one of its drugs, poziotinib, did not get the U.S. Food and Drug Administration's designation of "breakthrough therapy." The drug is designed to treat certain types of lung cancer. The company's overall development plan and timeline for a New Drug Application remains unchanged, it said. Breakthrough therapy designation is one of several FDA programs designed to expedite the review of drugs to treat serious or life-threatening conditions. "Our enthusiasm for poziotinib, our commitment to the program, and our overall development plan remain unchanged," Chief Executive Joe Turgeon said in a note. Spectrum ended the regular trading day down 1.5%.
Spectrum Pharmaceuticals, Inc. (SPPI), today announced that based on a subset of data from MD Anderson’s ongoing Phase 2 study, the U.S. Food and Drug Administration (FDA) did not grant Breakthrough Therapy Designation (BTD) to poziotinib for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have EGFR exon 20 mutations. Breakthrough Therapy Designation is one of several FDA programs designed to expedite the review of drugs to treat serious or life threatening conditions. Spectrum’s BTD application included data from 30 patients from the MD Anderson Phase 2 study who had failed platinum-based chemotherapy.
Spectrum Pharmaceuticals, Inc.'s (NASDAQ:SPPI): Spectrum Pharmaceuticals, Inc. develops and commercializes oncology and hematology drug products. With the latest financial year loss of -US$91.2m and a trailing-twelve month of -US$99.3m, the Read More...
Reputable billionaire investors such as Nelson Peltz and David Tepper generate exorbitant profits for their wealthy accredited investors (a minimum of $1 million in investable assets would be required to invest in a hedge fund and most successful hedge funds won’t accept your savings unless you commit at least $5 million) by pinpointing winning small-cap […]
The company announced third-quarter 2018 earnings and a pipeline update, but investors weren't happy with results from an important trial announced in early December.
Spectrum Pharma (SPPI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.